Using hypovolemic phlebotomy to improve laparoscopic liver surgery outcomes
Official title: The Application of Goal-directed Low Central Venous Pressure Based on Hypovolemic Phlebotomy in Laparoscopic Hepatectomy
Run by The First Affiliated Hospital with Nanjing Medical University · NCT05887661 · Data updated 2026-11-12
This study is testing whether a method that involves taking some blood out before liver surgery can help patients with liver cancer have safer surgeries and need fewer blood transfusions.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | May 1, 2022 |
| Main results expected | January 1, 2026 |
| Study ends | May 1, 2026 |
| Registry record updated | November 12, 2024 |
| Trial ID | NCT05887661 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults diagnosed with hepatocellular carcinoma who prefer laparoscopic hepatectomy.
✕Probably not a fit
Patients under 18, pregnant, or with significant cardiac, pulmonary, or renal conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of goal-directed low central venous pressure (LCVP) based on hypovolemic phlebotomy (HP) during laparoscopic hepatectomy for patients with hepatocellular carcinoma. The study aims to assess the safety and feasibility of HP and its potential to reduce the need for blood transfusions during surgery. Participants will have blood withdrawn prior to liver parenchymal transection to maintain a specific central venous pressure. A control group will undergo liver resection without HP for comparison.
Why it matters
Potential benefit: If successful, this approach could lead to safer laparoscopic liver surgeries with reduced blood transfusion requirements.
How similar studies have gone: While the specific approach of using HP in laparoscopic hepatectomy may be novel, similar studies have shown promising results in managing blood loss during surgeries.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of Hepatocellular Carcinoma * Preference for laparoscopic hepatectomy and patient agreement Exclusion Criteria: * Age \<18 years * Pregnancy * Refusal of blood product transfusion * Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure) * History of significant cerebrovascular disease * Restrictive or obstructive pulmonary disease * Uncontrolled hypertension * Renal dysfunction (glomerular filtration rate \<60 mL/min), * Hemoglobin \<100 g/L * Abnormal coagulation values (international normalized ratio \>1.5 not on warfarin and/or platelet count \<100 ×109/L) * Evidence of hepatic metabolic disorder (bilirubin \>35 mmol/L) * Presence of active infection * Preoperative autologous blood donation * Patients were not allowed to receive erythropoietin at any time during the index hospitalization.
Where it's running
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China Recruiting
Study contacts
- Principal investigator: Shijiang Liu, MD — The First Affiliated Hospital with Nanjing Medical University
- Study coordinator: Shijiang Liu, MD
- Email: liushijiang@jsph.org.cn
- Phone: +862568303569
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.